Novartis (NVS) closed at $150.60 on Oct 16, 2026, up 0.1% on the day. The stock is up 6.9% over the past month, up 0.7% over three months, up 12.6% year to date and up 19.4% over the past year. It trades 9.0% below its 52-week high of $165.43 and 27.6% above its 52-week low of $117.98. The close sits above its 50-day moving average ($148.24) and above its 200-day moving average ($150.03).
NextPick tracks NVS in its Pharma basket alongside JNJ, ABBV, MRK, RHHBY and AZN. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month NVS ranks 4th of 12 basket members by price change.
NVS is scheduled to report earnings on Oct 27, 2026. Over its last 8 reports the stock moved an average of 2.2% on the first trading day after earnings, beating the options-implied move in 3 of 7.
NVS options were pricing 26% at-the-money implied volatility on Oct 14, 2026, an IV rank of 50 over the past year.
Novartis is scheduled to report on Oct 27, 2026.
Over the last 8 reports, NVS moved an average of 2.2% on the first trading day after earnings. The move beat the options-implied move in 3 of 7 reports.
Yes — the Oct 16, 2026 close of $150.60 is 0.4% above the 200-day average of $150.03.
NVS closed 9.0% below its 52-week high of $165.43.
NextPick groups NVS with JNJ, ABBV, MRK, RHHBY and AZN in its Pharma basket.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
